Merxin Ltd and contract device manufacturer OECHSLERhealth have announced the formation of a strategic partnership called The SMI PowerHouse for manufacturing of Merxin’s MRX004 soft mist inhaler, a generic version of the Respimat device. According to the announcement, the two companies have worked together since 2018.
Merxin and OECHSLERhealth say that the partnership will have “pre-established manufacturing processes in place” that will accelerate development of SMI products and reduce upfront investment in devices for clients interested in using the MRX004 for their soft mist products.
Merxin Chief Business Officer Philippe Rogueda commented, “This partnership with OECHSLERhealth is hugely exciting. It brings to life our vision for The SMI Powerhouse, enabling quicker and more reliable access to market-ready SMIs while maintaining our focus on patient care and environmental stewardship.”
OECHSLERhealth Senior VP of the Health Business Unit Felix Hess said, “This partnership with Merxin Ltd. positions us to redefine the value chain of SMIs. Together, we’re raising the bar for accessibility, performance, reliability and innovation, helping our clients bring impactful inhalation therapies to patients faster.”
Read the Merxin and OECHSLERhealth press release.
